Basilea Pharmaceutica AG BPMUF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 247.22M | 243.65M | 235.10M | 239.34M | 244.71M |
| Total Other Revenue | 64.64M | 55.91M | 46.37M | 37.07M | 27.87M |
| Total Revenue | 311.85M | 299.56M | 281.48M | 276.40M | 272.58M |
| Cost of Revenue | 191.70M | 185.64M | 176.11M | 160.86M | 146.23M |
| Gross Profit | 120.16M | 113.92M | 105.36M | 115.54M | 126.35M |
| SG&A Expenses | 44.62M | 43.86M | 42.16M | 40.07M | 38.13M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 236.32M | 229.51M | 218.28M | 200.93M | 184.37M |
| Operating Income | 75.53M | 70.06M | 63.20M | 75.47M | 88.22M |
| Income Before Tax | 74.04M | 65.42M | 55.67M | 69.21M | 83.22M |
| Income Tax Expenses | 7.95M | 7.44M | 6.74M | 3.19M | -381.00K |
| Earnings from Continuing Operations | 66.08 | 57.97 | 48.94 | 66.01 | 83.61 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 66.08M | 57.97M | 48.94M | 66.01M | 83.61M |
| EBIT | 75.53M | 70.06M | 63.20M | 75.47M | 88.22M |
| EBITDA | 78.09M | 73.08M | 66.64M | 78.78M | 91.41M |
| EPS Basic | 5.37 | 4.72 | 4.00 | 5.42 | 6.89 |
| Normalized Basic EPS | 3.77 | 3.35 | 2.88 | 3.59 | 4.32 |
| EPS Diluted | 5.06 | 4.49 | 3.84 | 5.06 | 6.31 |
| Normalized Diluted EPS | 3.39 | 3.07 | 2.64 | 3.23 | 3.84 |
| Average Basic Shares Outstanding | 49.22M | 49.10M | 48.97M | 48.82M | 48.68M |
| Average Diluted Shares Outstanding | 54.66M | 53.39M | 53.43M | 53.80M | 54.16M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |